DCTH Delcath Systems Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DCTH

Price (delayed)

$12.87

Market cap

$444.29M

P/E Ratio

643.5

Dividend/share

N/A

EPS

$0.02

Enterprise value

$403.89M

?
Relative Growth: Rel. Growth: 85
Relative Strength: Rel. Strength: 69
Relative Valuation: Rel. Valuation: 14
Relative Profitability: Rel. Profitability: 59

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is ...

Highlights
Delcath Systems's gross profit has soared by 70% YoY and by 6% from the previous quarter
The company's revenue has surged by 68% YoY and by 6% QoQ
The net income has soared by 104% YoY but it has plunged by 79% from the previous quarter
Delcath Systems's EPS has soared by 104% YoY but it has plunged by 75% from the previous quarter
The price to earnings (P/E) is 150% higher than the last 4 quarters average of 257.3
Sector: Healthcare
Industry: Medical Devices
Website: http://www.delcath.com
Peers: ICUI ANGO PODD RVP

Key stats

What are the main financial stats of DCTH

DCTH stock price

How has the Delcath Systems stock price performed over time
Intraday
-1.08%
1 week
-4.53%
1 month
9.81%
1 year
13.49%
YTD
27.43%
QTD
2.22%

Financial performance

How have Delcath Systems's revenue and profit performed over time
Revenue
$90.44M
Gross profit
$77.75M
Operating income
-$1.69M
Net income
$561,000
Gross margin
86%
Net margin
0.6%
The net income has soared by 104% YoY but it has plunged by 79% from the previous quarter
Delcath Systems's net margin has surged by 102% YoY but it has shrunk by 81% QoQ
Delcath Systems's gross profit has soared by 70% YoY and by 6% from the previous quarter
The company's revenue has surged by 68% YoY and by 6% QoQ

Price vs fundamentals

How does DCTH's price correlate with its fundamentals

Growth

What is Delcath Systems's growth rate over time

Valuation

What is Delcath Systems stock price valuation
P/E
643.5
P/B
3.97
P/S
5.13
EV/EBIT
206.49
EV/EBITDA
170.49
EV/Sales
4.47
The price to earnings (P/E) is 150% higher than the last 4 quarters average of 257.3
Delcath Systems's EPS has soared by 104% YoY but it has plunged by 75% from the previous quarter
Delcath Systems's equity has increased by 40% YoY
DCTH's P/B is 13% higher than its last 4 quarters average of 3.5
The price to sales (P/S) is 69% less than the 5-year quarterly average of 16.3 but 4.7% more than the last 4 quarters average of 4.9
The company's revenue has surged by 68% YoY and by 6% QoQ

Efficiency

How efficient is Delcath Systems business performance
Delcath Systems's ROS has soared by 108% YoY but it has decreased by 46% from the previous quarter
The company's return on invested capital has surged by 106% YoY but it fell by 45% QoQ
The ROA has soared by 102% YoY but it has shrunk by 79% QoQ
The ROE has soared by 101% year-on-year but it has dropped by 81% since the previous quarter

Dividends

What is DCTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DCTH.

Financial health

How did Delcath Systems financials performed over time
DCTH's total liabilities has surged by 71% year-on-year but it is down by 2.3% since the previous quarter
The total assets has grown by 43% year-on-year
Delcath Systems's debt is 99% lower than its equity
Delcath Systems's equity has increased by 40% YoY
Delcath Systems's debt has decreased by 11% YoY and by 3.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.